Pharmacogenetics and anesthesiologists

Pharmacogenomics

Volumn 6, Issue 8, 2005, Pages 849-856

  Galley, Helen F ^a   Mahdy, Amr ^a   Lowes, Damon A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Analgesia; Anesthesia; Anesthesiology; Genetics; Pharmacodynamics; Pharmacokinetics; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CHOLINESTERASE; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DAPSONE; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; DIAZEPAM; DIGOXIN; ENDRALAZINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN P; HYDRALAZINE; MIDAZOLAM; MIVACURIUM; NITRAZEPAM; OPIATE RECEPTOR; PRIMAQUINE; PROCAINAMIDE; PROPAFENONE; RYANODINE RECEPTOR; SPARTEINE; SULFONAMIDE; SUXAMETHONIUM; THIOPENTAL; TRAMADOL; UNINDEXED DRUG;

ANESTHESIA; APNEA; CONCENTRATION RESPONSE; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; LUPUS VULGARIS; MALARIA; MALIGNANT HYPERTHERMIA; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPERTENSION; PARESTHESIA; PHARMACODYNAMICS; PHARMACOGENETICS; PORPHYRIA; POSTOPERATIVE PAIN; PROTEIN EXPRESSION; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; VISUAL IMPAIRMENT;

ANESTHESIOLOGY; ANESTHETICS; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DRUG;

EID: 28444485651     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.8.849     Document Type: Review

References (62)

1. Carsen PE, Flanagan CL, Iokes CE: Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124, 484-485 (1956).
2. Kalow W, Staron N: On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can. J. Med. Sci. 35, 1305-1320 (1957).
3. Gonzalez FJ, Skoda RC, Kimura S et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442-446 (1988).
4. Rogers JF, Nafziger AN, Bertino JS Jr: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 113, 746-750 (2002).
5. Mahgoub A, Idle JR, Dring LG: Polymorphic hydroxylation of debrisoquine in man. Lancet 2(8038), 584-586 (1977).
6. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C: Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin. Pharmacol. Ther. 31, 184-186 (1982).
7. Dahl ML, Iselius L, Alm C et al.: Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur. J. Clin. Pharmacol. 44, 445-450 (1993).
8. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90, 11825-11829 (1993).
9. Fagerlund TH, Braaten O: No pain relief from codeine? An introduction to pharmacogenomics. Acta Anaesthesiol. Scand. 45, 140-149 (2001).
10. Stamer UM, Lehnen K, Hothker F, Wolf S, Hoeft A: Impact of CYP2D6 on postoperative tramadol analgesia. Pain 105, 231-238 (2003).
11. Chow MS, White CM, Lau CP: Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. J. Clin. Pharmacol. 41, 92-96 (2001).
12. Floyd MD, Gervasini G, Masica AL et al.: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13, 595-606 (2003).
13. Kuehl P, Zhang J, Lin Y: Sequence diversity in CYP3A promoters and characterization of the genetic basis for polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
14. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H: CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther. 75, 529-538 (2004).
15. Kidd RS, Straughn AB, Meyer MC: Pharmacokenetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9, 71-80 (1999).
16. Blaisdell J, Mohrenweiser H, Jackson J et al.: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12, 703-711 (2002).
17. Lockridge O, Masson P: Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicol. 21, 113-126 (2000).
18. Ostergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J: Mivacurium induced neuromuscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiol. Scand. 37, 314-318 (1993).
19. Petersen RS, Bailey PL, Kalameghan R, Ashwood ER: Prolonged neuromuscular block after mivacurium. Anesthesiol. 76, 194-196 (1993).
20. Rosenberg MK, Lebenbom-Mansour M: Markedly prolonged paralysis after mivacurium in a patient apparently heterzygous for the atypial and usual pseudocholinesterase alleles by conventional biochemical testing. Anesth. Analg. 84, 457-460 (1998).
21. Gatke MR, Viby-Mogensen J, Ostergaard D, Budgaard JR: Response to mivacurium in patients carrying the K variant in the butyrylcholinesterase gene. Anesthesiol. 102, 503-508 (2005).
22. Ceppa F, Gidenne S, Benois A, Fontan E, Burnat P: Rapid identification of atypical variant of plasma butyrylcholinesterase by PCR. Clin. Chem. Lab. Med. 40, 799-801 (2002).
23. Butcher NJ, Boukouvala S, Sim E, Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenom. J. 2, 30-42 (2002).
24. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57, 581-592 (1995).
25. Clark DW: Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29, 342-375 (1985).
26. Spielberg SP: N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J. Pharmacokinet. Biopharm. 24, 509-519 (1996).
27. Brinkmann U, Roots I, Eichelbaum M: Pharmacogenetics of the human drug transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today 6, 835-839 (2001).
28. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000).
29. Ishikawa T, Tsuji A, Inui K-I et al.: The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 5, 67-99 (2004).
30. Brini M: Ryanodine receptor defects in muscle genetic diseases. Biochem. Biophys. Res. Commun. 322, 1245-1255 (2004).
31. Lötsch J, Geisslinger G: Are μ-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. 11, 82-89 (2005).
32. Uhl GR, Sora I, Wang Z: The μ-opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc. Natl Acad. Sci. USA 96, 7752-7755 (1999).
33. Caraco Y: Variability in alfentanil analgesia may be attributed to polymorphism in the μ-opiod receptor gene. Clin. Pharmacol. Ther. 69, 63 (2001).
34. Klepstad P, Rakvag TT, Kaasa S et al.: The 118A>G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48, 1232-1239 (2004).
35. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A: Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100; 120-133 (2004).
36. Lötsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G: The polymorphism A118G of the human μ-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12, 3-9 (2002).
37. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. 73, 107-121 (2003).
38. Romberg RR, Olofsen E, Bijl H et al.: Polymorphism of μ-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102(3), 522-530 (2005).
39. Koch T, Schulz S, Pfeiffer M et al.: C-terminal splice variants of the mouse μ-opioid receptor differ in morphine-induced internalization and receptor resensitization. J. Biol Chem. 276, 31408-31414 (2001).
40. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL: A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signalling. J. Biol. Chem. 276, 3130-3137 (2001).
41. Koch T, Kroslak T, Mayer P, Raulf E, Hollt V: Site mutation in the rat μ-opioid receptor demonstrates the involvement of calcium/calmodulindependent protein kinase II in agonist-mediated desensitization. J. Neurochem. 69, 1767-1770 (1997).
42. Xu K, Liu XH, Nagarajan S, Gu XY, Goldman D: Relationship of the δ-opioid receptor gene to heroin abuse in a large Chinese case/control sample. Am. J. Med. Genet. 110, 45-50 (2002).
43. Niemi G, Breivik H: The minimally effective concentration of adrenalinee in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenalinee after major surgery - a randomized, double-blind, dose-finding study. Acta Anes. Scand. 47, 439-450 (2003).
44. Steiner H, Gerfen CR: Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain. Res. 123, 60-67 (1998).
45. Chen JF, Aloyo VJ, Weiss B: Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases μ opioid receptors in mouse striatum: Neuroscience 54, 669-680 (1993).
46. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J: Kinetics of human soluble and membrane bound catechol O-methyltransferase: a revised mechanism and description of the termolabile variant of the enzyme. Biochemistry 34, 4202-4210 (1995).
47. Zubieta JK, Heitzeg MM, Smith YR et al.: COMT val158met genotype affects mu-opioid neurotransmitter response to a pain stressor. Science 299, 1240-1243 (2003).
48. Rakvåg TT, Klepstad P, Baar C et al.: The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116, 73-78 (2005).
49. Belelli I, Pistis I, Peters JA, Lambert JJ: General anaesthetic action at transmitter-gated inhibitory amino acid receptors. Trends Pharmacol. Sci. 20, 496-502 (1999).
50. Chou IC, Peng CT, Huang CC, Tsai JJ, Tsai FJ, Tsai CH: Association analysis of γ 2 subunit of γ-aminobutyric acid type A receptor polymorphisms with febrile seizures. Pediatr. Res. 54, 26-29 (2003).
51. A receptor α5 subunit gene polymorphism that may confound genotyping. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129, 27-28 (2004)
52. Lappalainen J, Krupitsky E, Remizov M et al.: Association between alcoholism and γ-amino butyric acid α2 receptor subtype in a Russian population. Alcohol Clin. Exp. Res. 29, 493-498 (2005)
53. Joo A, Shibata H, Ninomiya H, Kawasaki H, Tashiro N, Fukumaki Y: Structure and polymorphisms of the human metabotropic glutamate receptor Type 2 gene (GRM2): analysis of association with schizophrenia. Mol. Psych. 6, 186-192 (2001).
54. Siest G, Bertrand P, Herbeth B et al.:. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin. Chem. Lab. Med. 38, 841-852 (2000).
55. Kertai MD, Boersma E, Klein J, van Urk H, Poldermans D: Optimising the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch. Intern. Med. 165, 898-904 (2005).
56. Xing Y, Sonnet JM, Eger EI, Cascio M, Sessler DI: Mice with a melanocortin-1 receptor mutation have slightly greater MAC than control mice. Anesthesiology 101, 544-546(2004).
57. Liem EB, Lin C-M, Suleman M-I et al.: Increased anesthetic requirement in redheads. Anesthesiology 101, 279-283 (2004).
58. Liem EB, Joiner TV, Tsueda K, Sessler DI: Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficay in redheads. Anesthesiology 102, 509-514 (2005).
59. Urwyler A, Duefel T, McCarthy T, West S: A protocol of the investigation of malignant hyperpyrexia susceptibility. Br. J. Anaesth. 86, 283-287 (2001).
60. Sweeney BP: Do genes influence the outcome from anaesthesia? Br. J. Anaesth. 90, 725-727 (2003).
61. Schwinn DA, Booth JV: Genetics infuses new life into human physiology: implications of the human genome project for anesthesiology and perioperative medicine. Anesthesiology 962, 61-63 (2002).
62. Bukaveckas BL, Valdes R Jr, Linder MW: Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. J. Cardiothorac. Vasc. Anesth. 18, 353-365 (2004).